Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients

  • Ventura-Cots, Meritxell
  • Carmona, Isabel
  • Moreno, Carolina
  • Ampuero, Javier
  • Simón-Talero, Macarena
  • Sanpedro, Francesc
  • Les Bujanda, Íñigo
  • Romero-Gómez, Manuel
  • Genescà, Joan
Background: Episodes of hepatic encephalopathy (HE) have been related to low survival rate. However, the relation between its clinical evolution and mortality has not been assessed. Methods: A retrospective analysis of 245 cirrhotic patients admitted for an acute episode of HE (⩾grade 2) or who developed an HE episode after an upper gastrointestinal bleeding (UGIB) event was performed to assess the relation between time in HE and transplant-free survival. Results: Median (IQR25–75) time in HE was 48 h (24–96 h) in the whole cohort. Patients who presented a longer time in HE (>48 h; n = 89) exhibited a lower transplant-free survival at 28 days (67.2% versus 88.9%, p < 0.001), 90 days (48.7% versus 73.8%, p < 0.001) and 365 days (30.3% versus 53.2%, p < 0.001), as compared to those with less time in HE (⩽48 h; n = 156). Survival rates remained significantly different, with lower percentages in the group with time in HE >48 h, when comparing patients according to baseline HE grade (2 versus ⩾3) or model for end-stage liver disease (MELD) function (⩽15 versus >15). Time in HE was also an independent risk factor for mortality at each time point, hazard ratio (HR) (95 CI%) 28 days 2.59 (1.39–4.84); 90 days 1.98 (1.28–3.1) and 365 days 1.5 (1.08–2.19). Conclusions: The duration of the acute HE episode determines survival in cirrhotic patients independently of liver function and baseline HE grade., MST is a recipient of a Río Hortega grant from Instituto de Salud Carlos III, Spain. JG is a recipient of a Research Intensification grant from Instituto de Salud Carlos III, Spain. MVC is a recipient of a scholarship grant for study extension abroad, sponsored by the Spanish Association for the Study of the Liver. The study was partially funded by grants PI14/00331 and PI15/00066 from Instituto de Salud Carlos III, Spain and co-funded by European Union (ERDF/ESF, 'Investing in your future'). CIBERehd is supported by Instituto de Salud Carlos III, Spain.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals

  • Pons Delgado, Mònica|||0000-0002-0985-3320
  • Santos, Begoña
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Esteban, Rafael|||0000-0001-5280-392X
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
We aimed to investigate the early changes in liver and spleen stiffness measurement (LSM, SSM) in hepatitis C virus (HCV) patients with compensated advanced chronic liver disease (cACLD) treated with new antivirals (DAA) to elucidate factors determining the initial change in stiffness and its implications for the long-term follow up of HCV-cured patients. A total of 41 patients with cACLD who started DAA therapy underwent LSM and SSM at baseline, week 4, end of treatment (EOT), 24 and 48 weeks of follow up using transient elastography. LSM improved rapidly during the first 4 weeks of treatment (baseline: 20.8kPa; week 4: 17.5kPa, p = 0.002), with no significant changes between week 4 and EOT (18.3kPa, p = 0.444) and between EOT and 48-week follow up (14.3kPa, p = 0.148). Likewise, SSM improved rapidly (baseline: 45.7kPa; week 4: 33.8kPa, p = 0.047), with no significant changes between week 4 and EOT (30.8kPa, p = 0.153) and between EOT and 48-week follow up (31.2kPa, p = 0.317). A higher decrease in LSM was observed in patients with baseline ALT ⩾ twofold upper limit normal (2 × ULN) than in those with ALT < 2 × ULN (-5.7kPa versus -1.6kPa). Patients who presented a decrease in LSM ⩾ 10% during treatment compared with those with LSM < 10% decrease, showed lower SSM values, higher platelet counts and lower bilirubin levels at 24-week follow up. Those with decrease in SSM ⩾ 10%, presented a higher increase in platelets than those with SSM < 10% change (p = 0.015). LSM and SSM decrease very rapidly during DAA treatment in cACLD patients suggesting that it most probably reflects a reduction in inflammation rather than in fibrosis. cACLD patients should be maintained under surveillance independently of stiffness changes, because advanced fibrosis can still be present.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients

  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Carmona, Isabel
  • Moreno, Carol|||0000-0003-3275-0271
  • Ampuero, Javier|||0000-0002-8332-2122
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Sanpedro, Francesc
  • Les, Iñigo
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Episodes of hepatic encephalopathy (HE) have been related to low survival rate. However, the relation between its clinical evolution and mortality has not been assessed. A retrospective analysis of 245 cirrhotic patients admitted for an acute episode of HE (⩾grade 2) or who developed an HE episode after an upper gastrointestinal bleeding (UGIB) event was performed to assess the relation between time in HE and transplant-free survival. Median (IQR) time in HE was 48 h (24-96 h) in the whole cohort. Patients who presented a longer time in HE (.